Pregnancy outcome in women treated with doxorubicin for childhood cancer - 28/08/11
, Ofer Davidi, MD, Yacov Goshen, MD, Moshe Hod, MD, Itzhak Yaniv, MD, Rafael Hirsch, MD
Reprint requests: J. Bar, MD, Perinatal Division, Department of Obstetrics and Gynecology, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel.Tel Aviv, Israel
Abstract |
Objective |
Pregnancy outcome and the effect of pregnancy on cardiac function were assessed in women cured of childhood cancer.
Study design |
Forty women who received doxorubicin as part of a chemotherapy protocol for a neoplastic disorder in childhood were followed up at the same center during pregnancy and after delivery.
Results |
Thirty-seven women (72 pregnancies) completed follow-up. Pregnancy outcome was favorable in the 29 women with fractional shortening values of ≥30% before pregnancy, and their myocardial function was sustained. In 8 women with fractional shortening of <30% before pregnancy, pregnancy outcome was less favorable; a 19% decrease in fractional shortening was observed after pregnancy, and this finding was not significant (P=.08).
Conclusion |
Pregnancy outcome in women who received doxorubicin for malignancy in childhood is generally favorable. However, those with baseline left ventricular dysfunction should be considered at increased risk for worse pregnancy outcome and further deterioration in myocardial function.
Le texte complet de cet article est disponible en PDF.Keywords : Pregnancy outcome, doxorubicin therapy, childhood cancer, cardiotoxicity
Plan
 | Presented at the Twenty-Third Annual Meeting of the Society for Maternal-Fetal Medicine, San Francisco, Calif, February 3-8, 2003. |
Vol 189 - N° 3
P. 853-857 - septembre 2003 Retour au numéro
Article précédent
- A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia
- Celeste Durnwald, Brian Mercer
- Evaluation of a clinical skills orientation program for residents
- Peter E Nielsen, Robert H.B Holland, Lisa M Foglia
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?